Cargando…
Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile
A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. The majority of the new ligands dis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156383/ https://www.ncbi.nlm.nih.gov/pubmed/30283364 http://dx.doi.org/10.3389/fpsyt.2018.00430 |
_version_ | 1783358089759555584 |
---|---|
author | Kumar, Vinod Polgar, Willma E. Cami-Kobeci, Gerta Thomas, Mark P. Khroyan, Taline V. Toll, Lawrence Husbands, Stephen M. |
author_facet | Kumar, Vinod Polgar, Willma E. Cami-Kobeci, Gerta Thomas, Mark P. Khroyan, Taline V. Toll, Lawrence Husbands, Stephen M. |
author_sort | Kumar, Vinod |
collection | PubMed |
description | A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. The majority of the new ligands displayed high binding affinities for the three opioid receptors, and moderate affinity for NOP receptors. The affinities for NOP receptors are of particular interest as most classical opioid ligands do not bind to NOP receptors. The predominant activity in the [(35)S]GTPγS assay was partial agonism at each receptor. The results are consistent with our prediction that an appropriate 14β side chain would access a binding site within the NOP receptor and result in substantially higher affinity than displayed by the parent compound naltrexone. Molecular modeling studies, utilizing the recently reported structure of the NOP receptor, are also consistent with this interpretation. |
format | Online Article Text |
id | pubmed-6156383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61563832018-10-03 Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile Kumar, Vinod Polgar, Willma E. Cami-Kobeci, Gerta Thomas, Mark P. Khroyan, Taline V. Toll, Lawrence Husbands, Stephen M. Front Psychiatry Psychiatry A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. The majority of the new ligands displayed high binding affinities for the three opioid receptors, and moderate affinity for NOP receptors. The affinities for NOP receptors are of particular interest as most classical opioid ligands do not bind to NOP receptors. The predominant activity in the [(35)S]GTPγS assay was partial agonism at each receptor. The results are consistent with our prediction that an appropriate 14β side chain would access a binding site within the NOP receptor and result in substantially higher affinity than displayed by the parent compound naltrexone. Molecular modeling studies, utilizing the recently reported structure of the NOP receptor, are also consistent with this interpretation. Frontiers Media S.A. 2018-09-19 /pmc/articles/PMC6156383/ /pubmed/30283364 http://dx.doi.org/10.3389/fpsyt.2018.00430 Text en Copyright © 2018 Kumar, Polgar, Cami-Kobeci, Thomas, Khroyan, Toll and Husbands. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Kumar, Vinod Polgar, Willma E. Cami-Kobeci, Gerta Thomas, Mark P. Khroyan, Taline V. Toll, Lawrence Husbands, Stephen M. Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
title | Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
title_full | Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
title_fullStr | Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
title_full_unstemmed | Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
title_short | Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
title_sort | synthesis, biological evaluation, and sar studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives: ligands with mixed nop and opioid receptor profile |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156383/ https://www.ncbi.nlm.nih.gov/pubmed/30283364 http://dx.doi.org/10.3389/fpsyt.2018.00430 |
work_keys_str_mv | AT kumarvinod synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile AT polgarwillmae synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile AT camikobecigerta synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile AT thomasmarkp synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile AT khroyantalinev synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile AT tolllawrence synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile AT husbandsstephenm synthesisbiologicalevaluationandsarstudiesof14bphenylacetylsubstituted17cyclopropylmethyl78dihydronoroxymorphinonesderivativesligandswithmixednopandopioidreceptorprofile |